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Influenza is a vaccine-preventable acute respiratory viral infection, which causes epidemics annually around the globe. During annual influenza epidemics 3–5 million people 
develop severe disease and 250 000–500 000 people 
die due to influenza-related complications.1 All age 
groups are affected by influenza with the greatest risk 
of complications in children aged below two years, 
adults above 65 years, pregnant women, and people 
of any age with underlying medical conditions 
including immunosuppression.1,2
In an effort to develop evidence-based strategies 
to fight against influenza, the World Health 
Organization (WHO) established a Global Influenza 
Surveillance and Response System (GISRS) in 1952 
to monitor influenza viruses.3 GISRS also serves as a 
global alert mechanism for the emergence of influenza 
viruses with pandemic potential. Virological data 
collected from member states through GISRS enable 
the WHO to make recommendations for vaccine 
composition annually. Although the WHO has been 
monitoring influenza since 1952, several countries 
in various regions of the world have not established 
influenza surveillance systems and continue to lack 
vaccination programs.4–6
Influenza vaccines are the most effective way 
to prevent infection and reduce the severity of the 
disease.7 Safe and effective vaccines have been used 
for over 60 years around the world.7,8 In 2012, the 
WHO recommended pregnant women be given the 
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A B S T R AC T
Objectives: Influenza is a vaccine-preventable acute respiratory viral infection that 
causes epidemics annually around the globe. A regional influenza stakeholder network 
(MENA-ISN) comprised of experts assessed the status of influenza prevention and 
control using a structured survey. Methods: A survey questionnaire was used to obtain 
information from each participating country on surveillance system, the burden of 
disease, influenza vaccination programs, recommendations, funding and access for 
vaccine and vaccination, target rate, coverage rate monitoring, and drivers and barriers 
to influenza vaccination. Results: Out of the 10 countries that participated, nine had 
an influenza surveillance system and vaccination policy, and seven had World Health 
Organization (WHO) accredited reference laboratory. Three countries had burden of 
disease data available and eight had a reimbursement vaccine policy. Influenza vaccine was 
available in five countries through the Ministry of Health whereas in others, pharmacies 
also dispensed for the private sector. In all countries, prescribers were physicians, and 
vaccinators, which could be physicians, nurses, and pharmacists. Eight countries had a 
set vaccination target rate and only three monitored the influenza coverage rates. Drivers 
and barriers of vaccination were similar in all countries. Conclusions: Despite existing 
policies, influenza vaccination coverage remains far below the WHO recommendations. 
Increased awareness and effective implementation of policies with collaboration of 
stakeholders can help increase the rates to reach WHO targets.
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highest priority for influenza vaccination, and also 
recommended vaccination for healthcare workers 
(HCWs), children aged 6–59 months, the elderly, 
and persons with chronic medical conditions, in no 
order of priority.7 Despite the WHO vaccination 
recommendations and compiling scientific evidence 
on influenza burden and awareness, vaccination 
coverage rates remain low in Middle East and North 
African (MENA) countries.9–13 In addition, prior to 
very recent publications on the burden of influenza 
from Egypt, Iran, and Tunisia in collaboration with 
WHO/Eastern Mediterranean Region (EMRO), 
only a handful of countries such as Oman and Turkey 
had previously published studies on the burden of 
influenza in the MENA region.14–18
In line with the WHO’s Global Action Plan for 
Influenza Vaccines objectives to increase influenza 
awareness, a regional influenza stakeholder network 
(MENA-ISN) was established in 2014.19 MENA-
ISN is comprised of experts from basic and clinical 
sciences and officials from Ministry of Health 
(MOH) from Algeria, Egypt, Iran, lebanon, libya, 
Jordan, Kingdom of Saudi Arabia (KSA), Morocco, 
Oman, Tunisia, Turkey, and united Arab Emirates 
(uAE). In order to enable better planning for 
actions to be taken that will help increase influenza 
awareness and vaccination coverage rates, MENA-
ISN conducted a survey to collect data on the 
current status of influenza prevention and control 
in Algeria, Iran, KSA, lebanon, libya, Morocco, 
Oman, Tunisia, Turkey, and the uAE. The survey 
was conducted in countries where at least one 
MOH official was available to confirm the data. 
The collected data explored the existence of 
surveillance systems, vaccine recommendations, 
and influenza programs in each country. Herein, 
we provide a snapshot of the regional status of 
influenza prevention and control based on this 
survey results and published data when available 
from these countries.
M ET H O D S
Data collection was done using a survey questionnaire 
to obtain information in four categories from each 
participating country:
1. Existence of surveillance system and availability of 
burden of disease data.
2. Influenza vaccination programs, recommendations, 
and funding for vaccine/vaccination.
3. Access to the vaccine, vaccination target rate, and 
coverage rate monitoring.
4. Drivers and barriers to influenza vaccination.
Information was collected by face-to-face 
interviews or through telephone interviews with 
contact persons in national surveillance laboratories, 
public health institutions, and the national influenza 
coordinator in Algeria, Iran, KSA, lebanon, libya, 
Morocco, Oman, Tunisia, Turkey, and the uAE 
between September 2014 and April 2017. Ethical 
approval was not required for this study as it was 
based on secondary data and did not include human 
subjects. The data and information provided were 
further verified by the authors.
R E SU LTS
Nine out of 10 (90.0%) countries reported established 
surveillance systems. Surveillance was general/family 
practice-based in Algeria and hospital-based in 
lebanon and Oman. In Iran, libya, KSA, Morocco, 
Tunisia, and Turkey surveillance was based both on 
general practice and hospitals. The uAE was the only 
country without a surveillance system [Table 1]. 
Seven out of 10 (70.0%) countries had a WHO-
accredited laboratory designated as a national 
influenza center (NIC). libya and KSA reported 
having only regional laboratories that had not yet been 
accredited by the WHO. At the time of data collection, 
burden of disease data was only available from Algeria, 
Iran, Oman, and partially from Turkey [Table 1].
Nine out of 10 countries (90.0%) had a vaccination 
program [Table 2]. Vaccine recommendations at 
varying degrees existed in all countries except in 
lebanon where there was only a press release from 
the MOH to the public encouraging certain high-
risk groups to get vaccinated. Groups recommended 
to receive vaccination were somewhat in line with 
WHO recommendations.3 Persons with chronic 
medical conditions and HCWs were the most 
commonly (80.0%) recommended groups, followed 
by pregnant women (70.0%), and the elderly 
and pilgrims (60.0%) [Table 2]. In Tunisia, only 
2–5-year-old children with underlying conditions 
were recommended for vaccination and not adults 
with underlying health conditions. Only KSA 
recommended vaccination to healthy children aged 
6–59 months.
In eight out of 10 (80.0%) countries, a 
reimbursement policy existed for vaccine-
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recommended groups. Among these countries, 
Iran provided vaccine free of charge to vaccine-
recommended groups. lebanon and the uAE did not 
have a reimbursement policy. In lebanon, patients 
either paid out of pocket or private insurance covered 
the vaccination in limited numbers whereas in the 
uAE private insurance did not cover the vaccination, 
patients paid out of their pocket. In five countries, 
private insurances also covered vaccination [Table 
2]. Persons who did not belong to the risk groups 
either paid out of pocket or, if available, private 
insurance paid for the vaccination [Table 2].
In six out of 10 (60.0%) countries, pharmacies 
were the retailers. In these countries, MOH 
dispensed the vaccine for recommended groups 
either at vaccination centers or hospitals, or through 
vaccine institutes [Table 3]. In libya, the uAE, 
Tunisia, and Morocco, pharmacies did not play a 
role as vaccine retailers; vaccines were available only 
through MOH or related institutions.
In all countries, prescribers were physicians. 
In general, physicians, nurses, and pharmacists 
were the vaccinators at varying distribution in 
all countries [Table 3].
All countries with defined risk groups except 
Iran and Turkey had set a target rate for vaccination 
at varying levels depending on the risk group 
[Table 3]. Algeria had a fixed target rate of 35.0% for 
all vaccine-recommended groups. For KSA, libya, 
Morocco, Oman, and Tunisia depending on the risk 
group, the target rate ranged from 10.0% to 75.0%, 
20.0% to 90.0%, 100%, 90.0 to100%, 5.0% to 90.0%, 
respectively. Among all of these countries with a 
set target rate, KSA, libya, and Oman declared 
monitoring the coverage rate. However, the achieved 
rate was not disclosed.
Reported drivers and barriers of influenza 
vaccination for each country are listed in Table 4. 
Reported drivers and barriers were the professional 
views of the interviewed persons and the field 
experience of MENA-ISN members. However, for 
countries like Turkey and Oman, published data 
were available on drivers and barriers.12,14 Among the 
reported barriers, perceived low vaccine effectiveness, 
fear of side effects, lack of recommendation by 
doctors, and negative media were the major 
barriers for vaccination. The major drivers were 
the awareness of disease severity, recommendation 
Table 1: Existence of surveillance system and availability disease burden data.
Country Existence of surveillance and laboratory Availability 
of disease 
burden data
Does surveillance 
exist?
Surveillance 
GP/FP-based
Surveillance
hospital-based
Does laboratory exist
NIC Other
Algeria yes yES NO yES NO yes, in the 
annual report 
of the National 
Institute of 
Public Health
Iran yes yes yes yes yes yes
KSA yes yes yes No Regional No
lebanon yes No yes yes No No
libya yes yes yes No Central at 
MOH
No
Morocco yes yes yes yes Regional No
Oman yes NA yes yes Central at 
MOH
yes
Tunisia yes yes Initiated in six 
hospitals in 
2015–2016 
season
yes No No
Turkey yes* yes yes yes yes Partial, but not 
by MOH
uAE No NA NA No No No
GP/FP: general practice/family practice; NIC: national influenza center; KSA: Kingdom of Saudi Arabia;  
UAE: United Arab Emirates; MOH: Ministry of Health; NA: not applicable. 
*Surveillance is sentinel in Turkey.
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Table 3: Access to vaccine, vaccination target rate, and coverage rate monitoring.
Country Access to vaccine Vaccination coverage
Prescriber Dispenser*/retail** Vaccinator Target rate for 
risk groups, %
Monitoring
Algeria Physicians MOH and pharmacies Physicians, nurses,  and
pharmacists
35.0 No
Iran MOH 
physicians/HCPs
MOH and pharmacies HCW No No
KSA Physicians MOH, non-MOH 
hospitals, private clinics, 
pharmacies
Physicians, nurses, and 
pharmacies
10.0–75.0 yES, for the 
whole population
lebanon Physicians and
pharmacies
Physicians and
pharmacies
Physicians and
pharmacies
No No
libya Physicians Vaccination centers at 
MOH
Physicians and
nurses
20.0–90.0 yes, for some risk 
groups
Morocco MOH physicians 
for HCWs
NA NA 100 NA
Oman Physicians MOH and pharmacies EPI Staff and nurse 90.0–100 yes
Tunisia Physicians MOH Physicians 5.0–90.0 No
Turkey Physicians MOH for HCW only and
pharmacies
Physicians and nurses No No
uAE Physicians MOH and private Physicians and nurses No No
KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates; HCW: healthcare worker; MOH: Ministry of Health; HCPs: healthcare practitioners, 
 EPI: extended programme of immunization.*MOH purchases the vaccine through tender for public market and dispenses it to the related institutions/doctors. 
**Pharmacies are the retailers that sell the vaccines.
Table 4: Motivators and barriers for influenza vaccination.
Country Vaccination motivators Vaccination barriers
Algeria  ■ Disease severity leading to death
 ■ Prevention of death by vaccination
 ■ WHO NIC available for advice
 ■ HCW
 ■ Lack of information (lack of vaccine communication 
outside flu season)
 ■ Fear of side effects
 ■ Lack of scientific communication on the effectiveness
Iran  ■ Doctors recommendation, MOH recommendation
 ■ Free of charge coverage for high-risk population such as 
HIV patients
 ■ Low public awareness, low acceptance, and belief in some 
HCP, side effects (like Guillain-Barre syndrome), no 
coverage by main insurance facilities
KSA  ■ HCW: MOH interest, local global recommendations, 
easy vaccination process, data, education
 ■ Lay public: Doctor’s recommendation, free vaccination, 
awareness
 ■ HCW: Not convinced, logistical barriers such as 
equipment, time consumption, infrastructure
 ■ Lay public: Lack of awareness
lebanon  ■ Awareness in some segments of the population
 ■ Previous encounters with influenza
 ■ Fear of side effects
 ■ Impression it is ineffective
 ■ Providers not always recommending strongly
libya  ■ High awareness  ■ No barriers
Morocco  ■ HCP are concerned for the risk groups
 ■ Awareness campaign at the start of the season
 ■ Vaccine reimbursement for some populations (insurance)
 ■ Fear of side effects
 ■ Doubts on vaccine effectiveness
 ■ Health care workers not convinced
 ■ No public awareness campaign at the national level
 ■ Disease severity is under-recognized
 ■ Negative effect of media during 2009 pandemic
Oman  ■ National Disease Morbidity and Mortality  ■ No barriers
Tunisia  ■ Awareness of the need for protection of high-risk groups  ■ No barriers
Turkey  ■ Fear of complications and death
 ■ Doctor’s recommendation
 ■ Negative media coverage about the vaccine
 ■ Fear of side effects
 ■ Distrust in vaccine effectiveness
uAE  ■ Knowledge of disease and its severity  ■ Lack of effectiveness
 ■ The negative effect of media
WHO: world health organization; NIC: national influenza center Laboratory; KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates; MOH: Ministry 
of Health; HCP: Healthcare practitioner; HCW: Healthcare worker; NA: not applicable.
288 Sa l a h  A l  Awa i d y,  et  a l .
O M A N  M E D  J,  V O l  3 3 ,  N O  4 ,  J u ly  2 0 1 8
289Sa l a h  A l  Awa i d y,  et  a l .
by doctors, previous encounters with influenza, 
belief in protection by vaccines, and local/global 
recommendations. In KSA, interest from MOH, and 
in Oman availability of disease burden data played as 
major drivers for HCWs to vaccinate [Table 4].
D I S C U S S I O N
Surveillance is an important tool to monitor 
influenza virus circulation patterns and document 
disease burden, which is necessary for setting public 
health priorities and developing effective control 
programs including vaccination. In addition, 
increasing the number of countries participating 
in GISRS will increase the diversity and volume of 
viruses shared with WHO collaborating centers. 
Evaluation and inclusion of viruses from diverse areas 
may allow better prediction of the vaccine reference 
viruses increasing the likelihood of match between 
circulating viruses and the vaccine.20 According to 
our survey, the majority (90%) of countries had 
a national surveillance system. The uAE was the 
only country without established surveillance. 
Respiratory virus surveillance was established in 
KSA in 2017. One of the most important religious 
mass gatherings, Hajj, takes place in Mecca. 
Therefore, establishing a sustained respiratory virus 
surveillance will provide information on influenza 
and other emerging respiratory viruses, which 
will guide the development of effective control 
measures in KSA. Although surveillance existed in 
the majority of countries, many countries did not 
use the data collected to determine the burden of 
disease. According to the survey, disease burden 
data at varying levels was available only from 
Algeria, Iran, Oman, and Turkey. Algeria and Iran 
indicated that disease burden data were available 
only in the MOH annual report whereas for Oman 
and Turkey data was published in peer-reviewed 
journals.12–15 However, as this manuscript was being 
written, influenza disease burden data concerning 
only the incidence of influenza confirmed severe 
acute respiratory illness cases for Iran, Egypt, and 
Tunisia was published in the July 2016 issue of 
Eastern Mediterranean Health Journal (EMHJ).16–18 
In the same issue of the EMHJ, influenza outbreak 
characterization from other regional countries such 
as Jordan, lebanon, Morocco, and yemen were also 
published.21–24 This is a step forward in the Eastern 
Mediterranean region; however, to establish effective 
prevention policies, more data including the health 
and economic burden of influenza over several 
seasons in the regional countries is needed.
Most countries in the developed world have a 
national immunization policy against influenza.6 
In our survey, lebanon was the only country 
without a national policy in the region. Countries 
with a national policy recommended the vaccine 
to risk groups aligned defined by WHO and many 
supported their recommendation financially by 
various forms of reimbursement, or free supply of 
the vaccine.7 Vaccination of pregnant women has 
been shown to be safe and effective in preventing 
disease, and even cost-effective.7 According to 
WHO recommendations, pregnant women should 
be given the highest priority in countries starting or 
expanding seasonal influenza vaccination programs. 
Recommendation for pregnant women already exists 
in 70% of MENA countries included in the survey. 
However, influenza vaccine recommendations 
for healthy children only exist in KSA. Vaccine 
recommendation to healthy children is not optimal 
in most European countries either.25 Children are 
important in the transmission of influenza and herd 
immunity benefits of pediatric vaccination programs 
have been documented.26 Therefore, the inclusion of 
children in vaccination policies might help reduce 
the burden of influenza.
Pilgrimage to Mecca is a major mass gathering 
event where people from all over the world come 
together for a few days, thus increasing the risk of 
contracting influenza and taking it back to the 
pilgrim’s country of origin.27 Although not included 
in the vaccine-recommended risk groups by WHO, 
vaccination of local pilgrims is mandatory in KSA 
[Table 1]. This is also an indication that influenza is 
considered as a health threat in the region.
Those countries with recommendations also had 
a reimbursement policy at varying levels. However, 
despite the recommendations and reimbursement 
schemes, vaccination coverage remains low (3%) 
in the surveyed countries.13 The WHO launched 
Global Action Plan for Influenza Vaccines (GAP) in 
2006, a-10 year initiative to address the anticipated 
shortfall in vaccine supply in the event of a pandemic, 
with three main objectives: 1) increase in seasonal 
vaccine use, 2) increase in vaccine production 
capacity, and 3) research and development.19 Within 
this context, global vaccine production has increased 
since 2006. However, vaccine utilization has not 
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increased accordingly. According to survey results, 
the vaccine was recommended for the risk groups 
in all countries, and a vaccination target rate was set 
in 60.0% of these countries. However, vaccination 
coverage rate monitoring was conducted only in 30.0% 
of the countries. Setting a target rate, monitoring the 
vaccination coverage rates, and measuring vaccine 
effectiveness are key for evaluating a vaccination 
program. This is important especially in resource-
limited settings which will allow the countries to 
modify their vaccination programs accordingly.
There is a need for determining the vaccine 
prescribers and vaccinators to estimate targets for 
awareness training as needed. Physicians, nurses, 
and pharmacists were the most frequently cited 
vaccinators in the region.
The drivers and barriers of the vaccination in 
this region were similar to those published in other 
countries around the world.12 Major drivers were the 
awareness of disease severity and recommendation 
by the doctors. Major barriers were low vaccine 
effectiveness and fear of side effects [Table 4]. Interest 
from the MOH seemed to have a direct effect on 
HCWs to vaccinate in KSA.
Countries with surveillance systems indicated 
that virus sharing and reporting to WHO is not 
always optimal, a potential area of improvement. A 
recent publication also reported that a few countries 
in the WHO/EMRO region send adequate number 
of viruses regularly to WHO collaborating centers 
indicating the need for improved virus sharing 
in order to improve the effectiveness of vaccine 
virus selection.20 Countries also indicated that 
dissemination and use of surveillance data needed 
improvement. A recently-launched platform, eastern 
mediterranean Flu for sharing epidemiological 
and virological data on influenza in the WHO 
Eastern Mediterranean Region may help in better 
dissemination of surveillance data in the region.28
This survey provides information on areas that 
need to be improved to document disease burden, 
increase influenza awareness, and vaccination 
coverage rates. Survey results indicate that issuing 
policies in line with WHO recommendations and 
reimbursement alone is not sufficient to increase 
awareness and the vaccination coverage rates (VCRs). 
The policies need to be implemented with sustained 
determination to increase VCR. Monitoring VCR 
and documenting the burden reduced by vaccination 
is key to evaluating vaccine policies. Continuing 
guidance and support from WHO on developing 
and implementing effective immunization policies 
based on scientific evidence might help reduce 
the burden of influenza in regional countries. In 
addition, MENA-ISN-like networks can facilitate 
influenza awareness and vaccine advocacy by 
communicating scientific data, WHO policies, and 
guidelines developed by scientific organizations with 
all stakeholders including policymakers, HCWs, and 
the general public.
The purpose of the survey was to take a snapshot 
that gives a general idea about the status of influenza 
prevention and control in selected countries in the 
MENA region. The questions in the survey were 
answered by officials in the surveillance laboratories 
and MOHs public health institutions. We could not 
include all countries in the MENA region in this 
study due to MOH refusal to provide data. Despite 
the limitations, the results provide an updated 
picture of influenza policies and status of influenza 
prevention and control in the countries surveyed.
C O N C LU S I O N
Survey results indicate that developing influenza 
prevention plans alone is not sufficient to increase 
influenza vaccination coverage in vaccine-
recommended groups. Increasing the vaccination 
rate against influenza requires development and 
successful implementation of vaccination programs 
by health authorities.
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